Copaxone® 20 mg/ml er ikke længere kontraindiceret under graviditet Produktresumeet for Copaxone® (glatirameracetat) 20mg/ml (daglig subkutan injektion), som anvendes til behandling af attakvis multipel sklerose (MS), er blevet opdateret, så præparatet ikke længere er kontraindiceret under graviditet. Det er gode nyheder for kvinder med MS, som planlægger graviditet.

Program MS gruppeophold

awasa

  Whatever you want is here

Her kan du se en liste over vores sponsorer:  Link til sponsors Foreningen Sclerose.info blev stiftet i 2002. Foreningen er en NGO – Non Govermental Organisation, som er en ikke offentlig støttet forening. Alle foreningens midler kommer fra sponsorater og fra private donationer. Foreningen bruger sine midler på informationsarbejde om sclerose som følger foreningens mål “udbrede

Merck Serono’s Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial •Two-year primary efficacy endpoint of CLARITY trial met: 58% relative reduction in annualized relapse rate in the low total dose treatment group and 55% in the high total dose treatment group •Submission for registration of

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif®